Drug Monograph
Full clinical overview, indications, dosage references & safety notes.
Overview
Glucosamine/Chondroitin sulfate (Cosequin®) is a dietary supplement commonly used in dogs and cats as an adjunctive therapy for osteoarthritis and other chronic painful conditions. It is not an FDA-approved drug, and its clinical efficacy remains variable and somewhat controversial. These compounds are generally well tolerated and may be used long-term, including in patients where other treatments (such as NSAIDs) are contraindicated.
Mechanism of Action (MOA): Glucosamine serves as a precursor for glycosaminoglycans and hyaluronan, which are essential components of articular cartilage. It may support cartilage repair and has mild anti-inflammatory effects. Chondroitin sulfate contributes to cartilage integrity by stimulating proteoglycan production and inhibiting degradative enzymes within joints.
Onset of clinical benefit is typically delayed, requiring approximately 2–6 weeks (or longer) of continuous administration before improvement may be observed.
Indications
Glucosamine and chondroitin sulfate are used in dogs and cats as adjunctive therapy for chronic musculoskeletal and joint-related conditions. Their clinical benefit is variable, but they are commonly included as part of a multimodal management plan.
- Osteoarthritis: Used to support joint health and potentially improve mobility, stiffness, and lameness in dogs and cats with degenerative joint disease.
- Chronic pain conditions: May be used as an adjunct to other therapies (e.g., NSAIDs) for long-term management of joint pain.
- Multimodal therapy: Often combined with other treatments such as NSAIDs, weight management, and physical therapy to enhance overall clinical outcome.
- Feline lower urinary tract disease (FLUTD): N-acetyl glucosamine has been investigated for potential benefit in cats, although results are inconsistent.
Dosage (Reference)
Dog
In dogs, dosing recommendations are largely empirical due to variability between products and lack of standardized formulations. Dosing is typically based on the chondroitin component and adjusted according to clinical response.
| Clinical use | Route | Dose | Notes |
|---|---|---|---|
| Chronic pain / osteoarthritis (initial) | PO | 15–30 mg/kg (chondroitin component) | Used as adjunctive therapy; product-dependent dosing. |
| Maintenance therapy | PO | Same dose reduced by ~50% or every other day | After 4–6 weeks if clinical improvement is observed. |
• Dose is based on the chondroitin content, not total product weight.
• Large variability exists between products—follow label recommendations when available.
• Onset of effect is slow (typically 2–6 weeks).
• Often used in combination with NSAIDs for improved clinical outcome.
• If no response is observed after an adequate trial period, reassess therapy.
Cat
In cats, dosing is similar to dogs for joint disease, but additional specific dosing exists for certain conditions such as feline lower urinary tract disease.
| Clinical use | Route | Dose | Notes |
|---|---|---|---|
| Chronic pain / osteoarthritis | PO | 15–30 mg/kg (chondroitin component) | Same approach as dogs; adjust based on response. |
| Feline idiopathic cystitis (N-acetyl glucosamine) | PO | 250 mg/cat once daily | Fixed dose (NOT mg/kg); clinical benefit is inconsistent. |
• Fixed dosing may be used for some indications (e.g., 250 mg/cat).
• Product variability is significant—ensure consistency of formulation.
• Clinical response should be evaluated after 4–6 weeks of therapy.
• May be used long-term due to favorable safety profile.
Warnings & Precautions
Glucosamine and chondroitin supplements are generally considered safe, but variability in product quality and limited regulatory oversight require careful use and monitoring in clinical practice.
- Product variability: These are not FDA-regulated drugs; potency, purity, and bioavailability can vary widely between products.
- Hypersensitivity reactions: Possible, especially in products derived from shellfish; avoid in animals with known hypersensitivity.
- Asthma/bronchoconstrictive disease: Glucosamine may theoretically exacerbate respiratory conditions; use cautiously.
- Potassium content: Some glucosamine sulfate products contain significant potassium; use caution in patients requiring potassium-restricted diets.
- Reproductive safety: Safety in pregnant or lactating animals has not been established; use only if benefits outweigh risks.
- Delayed onset of action: Clinical improvement may take several weeks; premature discontinuation may lead to incorrect assessment of efficacy.
Drug Interactions
Clinically significant drug interactions are uncommon, but glucosamine and chondroitin may influence coagulation, glucose metabolism, or the effectiveness of certain drugs. Monitoring is recommended when used with the following medications.
- Anticoagulants (e.g., heparin, warfarin, rivaroxaban): High doses may enhance anticoagulant effects and increase the risk of bleeding.
- Antidiabetic agents (e.g., insulin, glipizide, metformin): Glucosamine may reduce the effectiveness of hypoglycemic drugs.
- Doxorubicin: Glucosamine may reduce therapeutic efficacy by inducing resistance (via effects on topoisomerase II).
Side Effects & Overdose
Side Effects
Glucosamine and chondroitin are generally well tolerated in dogs and cats, and adverse effects are uncommon and typically mild when they occur.
- Gastrointestinal: Mild effects such as flatulence or soft stools may occur.
- Hypersensitivity reactions: Possible, particularly with products derived from shellfish.
Overdose
Oral overdose is unlikely to cause significant toxicity. High doses are generally well tolerated, although mild gastrointestinal disturbances may occur.
- Clinical signs: Primarily GI upset (e.g., diarrhea, soft stools).
- Coagulation effects: Potential alterations in coagulation parameters have been suggested but not clearly documented.
- Manganese-containing products: Chronic excessive dosing may lead to manganese toxicity if present in the formulation.
- Management: Supportive care is usually sufficient.
Key Notes
Practical clinical considerations for the use of glucosamine/chondroitin in dogs and cats:
- Trial-based use: Clinical use is often based on individual patient response rather than predictable outcomes.
- Consistency of product: Switching between brands may alter clinical response due to differences in formulation.
- Adjunct—not primary therapy: Best used as part of a broader management plan rather than as sole treatment.
- Plateau effect: If improvement occurs, benefits tend to stabilize rather than continue increasing over time.
- Patient selection: May be more useful in early or mild joint disease compared to advanced cases.
